Sign inJoin waitlistJoin the waitlist

Naim Alkhouri

Chief Academic Officer · Summit Clinical Research

Credentials: · · · · · · ·

History

SSM Health/Saint Louis University School of Medicine
Present

Gastroenterology
Cleveland Clinic
2011–2014
Cleveland Clinic
2010–2011
Cleveland Clinic
2007–2010
Internal Medicine
Jefferson Health Medical Education
2004–2007
Damascus University-Faculty of Medicine
2001

Research

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
New England Journal of Medicine · 2024 · 1,637 citations
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
New England Journal of Medicine · 2021 · 646 citations
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet · 2019 · 640 citations

Mazen Noureddin
68 papers
SH
Stephen Harrison
40 papers
Ariel Feldstein
35 papers
Rohit Loomba
31 papers
Nizar Zein
29 papers
ZY
Zobair Younossi
27 papers
Eric Lawitz
25 papers
Arun Sanyal
23 papers
IH
Ibrahim Hanouneh
23 papers · 1 as a fellow
Mary Rinella
17 papers
AM
Arthur Mccullough
14 papers
Ashwani Singal
14 papers

Clinical trials

Phase 2a Study of HPG1860 in Subjects With NASH
Principal investigator · Completed · Phase 2
Hepagene (Shanghai) Co., Ltd.
2021–2023
Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients
Study director · Terminated
The Cleveland Clinic
2014–2015
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2026–2033
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2031